00:42 , Apr 19, 2019 |  BC Week In Review  |  Clinical News

BMS reports detailed survival data for failed Opdivo maintenance trial in SCLC

Bristol-Myers said Opdivo nivolumab plus Yervoy ipilimumab as maintenance therapy of extensive-stage disease small cell lung cancer following first-line platinum-based chemotherapy led to a median overall survival of 9.2 months vs. 9.6 months for placebo...
13:59 , Apr 9, 2019 |  BC Extra  |  Company News

BeiGene, BioAtla in deal for conditionally activated CTLA-4 inhibitor

BioAtla granted BeiGene a license to BA3071 (CAB-CTLA-4), a conditionally activated inhibitor of CTLA-4, that the partners will develop jointly to treat cancer. The companies plan to test the mAb as monotherapy and in combination...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
23:56 , Apr 4, 2019 |  BC Week In Review  |  Clinical News

Jounce reports detailed data backing tumor-agnostic approach

Jounce reported detailed PFS and OS data at AACR for vopratelimab (JTX-2011) that support a tumor-agnostic approach for the ICOS agonist to select patient populations more likely to respond to the therapy. At the American...
00:15 , Mar 9, 2019 |  BC Extra  |  Clinical News

Jounce seeking tumor-agnostic approach for ICOS agonist

Jounce said the ICOS hi CD4 T cells biomarker could allow the company to take a tumor-agnostic approach for its ICOS agonist vopratelimab (JTX-2011) to select patient populations more likely to respond to the therapy....
22:14 , Mar 1, 2019 |  BioCentury  |  Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
23:09 , Feb 26, 2019 |  BC Extra  |  Company News

CytomX R&D day reveals Probody toxicity, chopped BMS deal

CytomX Therapeutics Inc. (NASDAQ:CTMX) lost $6.03 (32%) to $13.13 on Tuesday after reporting severe toxicity signals with its CD166 Probody-drug conjugate, and disclosing that partner Bristol-Myers Squibb Co. (NYSE:BMY) terminated three targets under their discovery...
00:41 , Feb 9, 2019 |  BioCentury  |  Product Development

Genentech takes the wheel

Roche has good cause to call on Genentech to prevent it from losing its long-standing dominance in cancer. While the pharma is late to the party in immuno-oncology, its former biotech unit is behind at...
00:35 , Feb 1, 2019 |  BC Innovations  |  Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...